Mylan's (MYL) EpiPen Settlement with U.S. DOJ Seen as 'Significant' by BTIG; 'Buy' Rating Affirmed
- Apple (AAPL) Tops Q4 EPS by 2c; Issues Solid Outlook
- Wall Street slips on earnings; Apple falls late after results
- Chipotle Mexican Grill (CMG) Posts Q3 EPS of $0.27; Comps Miss Views; Additional Stock Buyback Approved
- Pandora (P) Misses Q3 EPS by 1c, Q4 Revenue Guidance Falls Short
- After-Hours Movers 10/25: (OGXI) (AKAM) (VRTX) Higher; (EW) (NUVA) (CMG) (AAPL) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
BTIG affirms Mylan N.V. (Nasdaq: MYL) at Buy with a price target of $55 after the company announced that its subsidiary, Mylan Inc., has agreed to the terms of a $465 million settlement with the U.S. Department of Justice and other government agencies that will resolve questions that have been raised about the classification of EpiPen Auto-Injector and EpiPen Jr Auto-Injector for purposes of the Medicaid Drug Rebate Program.
The firm commented,
We believe this settlement with the DOJ is significant and may put the EpiPen pricing controversy to rest. While a separate FTC investigation could still move forward, our channel checks with health policy contacts over the weekend suggest there is a low probability for that to occur given the size of the settlement. While we have lowered our CY16 and CY17 EPS forecasts to $4.70 and $5.58, to reflect lower Epipen sales going forward, we maintain our Buy rating on MYL shares based on the heavily discounted valuation and its strong position as a global generics Co.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Securities Starts Mylan (MYL) at Buy
- Intersil (ISIL) PT Bumped to $22 at Stifel
- Needham & Company Raises Price Target on II-VI, Inc. (IIVI) Following 1Q Beat
Create E-mail Alert Related CategoriesAnalyst Comments, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!